Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TBPH
TBPH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TBPH News
Theravance Biopharma Reports Q4 2025 Financial Results
Mar 19 2026
seekingalpha
Theravance Biopharma Reports Record Q4 2025 Results and Strategic Restructuring
Mar 19 2026
PRnewswire
Theravance Biopharma Restructuring Plan and Financial Performance
Mar 19 2026
Newsfilter
Theravance Biopharma Reaffirms Financial Guidance Amid Trial Failure Risks
Mar 18 2026
PRnewswire
Theravance Biopharma Reaffirms Financial Guidance Amid Trial Failure
Mar 18 2026
Newsfilter
Theravance Biopharma Reports Declining R&D Costs Post CYPRESS Enrollment
Mar 11 2026
Newsfilter
Wall Street Analysts Adjust Ratings
Mar 04 2026
Benzinga
Wall Street Analysts Adjust Ratings on Key Stocks
Mar 04 2026
Benzinga
Theravance Biopharma's Phase 3 Trial Fails to Meet Primary Endpoint
Mar 03 2026
Benzinga
Theravance Biopharma Cuts Workforce by 50% Amid Phase 3 Trial Failure
Mar 03 2026
stocktwits
U.S. Stocks Decline Amid Ongoing Iran-U.S. Conflict
Mar 03 2026
Benzinga
Theravance Biopharma Halts Clinical Program for Ampreloxetine
Mar 03 2026
seekingalpha
Theravance Biopharma Halts Ampreloxetine Program Following Phase 3 Study Failure
Mar 03 2026
PRnewswire
Theravance Biopharma's CYPRESS Study Fails to Meet Primary Endpoint
Mar 03 2026
Newsfilter
THERAVANCE BIOPHARMA INC ANNOUNCES COMPLETE R&D ORGANIZATION WIND-DOWN AND AROUND 50% REDUCTION IN G&A STAFF
Mar 03 2026
moomoo
THERAVANCE BIOPHARMA INC ANTICIPATES RESTRUCTURING WILL YIELD ANNUAL CASH FLOW OF ABOUT $60 - $70 MILLION
Mar 03 2026
moomoo
Show More News
